|
|
|
| Clinical effect of Pseudomonas Aeruginosa Injection combined with Cisplatin and local hyperthermia in the treatment of cancerous ascites |
| WANG Cui-hong1 SHI Wen-kui2 WANG Mao-mao1 FAN Yu-fei1▲ |
1.Department of Oncology,Beijing Yanhua Hospital
2.Department of Occupational Disease,Beijing Yanhua Hospital |
|
|
|
|
Abstract Objective To observe the clinical efficacy of Pseudomonas Aeruginosa Injection combined with Cisplatin and local hyperthermia in the treatment of cancerous ascites.Methods A total of 58 patients with cancerous ascites admitted to Beijing Yanhua Hospital from June 2016 to June 2019 were selected as the research objects,and they were divided into group A (19 cases),group B (19 cases) and group C (20 cases) according to the random number table method.After adequate drainage of ascites,group A was treated with Cisplatin,group B was received local hyperthermia after one hour of Cisplatin perfusion,while group C was treated with local hyperthermia one hour after infusion of Cisplatin,and was perfused with Pseudomonas Aeruginosa Injection three days later.Two weeks were a treatment cycle,totally two cycles after apart seven days.The ascites reduction,functional state score (KPS) and adverse reactions were assessed one month later..Results The total effective rate of ascites reduction in group C was higher than that in group A,the difference was statistically significant (P<0.05).The KPS score of group C after treatment was higher than that of group A,the difference was statistically significant (P<0.05).The improvement rate of KPS in group C was higher than that in group A,the difference was statistically significant (P<0.05).There were no significant difference in the total incidence of adverse reactions between group A and group B compared with group C (P>0.05),and there was no significant difference in the total incidence of adverse reactions between group A and group B (P>0.05).Conclusion Pseudomonas Aeruginosa Injection combined with Cisplatin and local hyperthermia has a good clinical effect in the treatment of cancerous ascites,and it can improve the functional status of patients.
|
|
|
|
|
|
| [1] |
贺显华.对恶性胸腹水患者进行腔内灌注化疗联合深部热疗的疗效探析[J].当代医药论丛，2019，17（19）：84-85.
|
| [4] |
周际昌，鲍云华，储大同，等.实用肿瘤内科学[M].2版.北京：人民卫生出版社社，2003：45-46，29-30.
|
| [5] |
吴照宇.MicroRNA 在恶性胸腹膜腔积液中的表达及诊断意义[J].实用癌症杂志，2016，32（1）：33-34.
|
| [6] |
王怀碧，江飞龙，赖宗浪，等.恶性腹水的治疗现状及进展[J].中国中医急症，2017，26（12）：2162-2164.
|
| [7] |
洪义东，胡楠，卞宝祥，等.铜绿假单胞菌注射液抗肿瘤作用及其相关机制的研究进展[J].中国现代应用药学，2019，36（2）：256-259.
|
| [2] |
Bekes I，Friedl TW，Kohler T，et al.Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion，thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?[J].Mol Cancer，2016，15：13.
|
| [3] |
Liu ZB，Hou YF，Zhu J，et al.Inhibition of EGFR pathway signaling and the etastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannosedependent manner[J].Oncogene，2010，29（20）：2996-3009.
|
| [8] |
沈预程，谢锦华，吉浩明.铜绿假单胞菌注射液、白介素-Ⅱ联合顺铂胸腔灌注治疗恶性胸腔积液临床研究[J].交通医学，2016，30（2）：179-180，183.
|
| [9] |
李朋朋，邝先奎，董文杰，等.铜绿假单胞菌注射液联合多西他赛和顺铂治疗肺癌所致恶性胸腔积液疗效观察[J].中华实用诊断与治疗杂志，2014，3（28）：296-297，300.
|
| [10] |
陈毅，朱鹏，张剑波.腹腔热灌注化疗治疗晚期胃癌恶性腹水的研究进展[J].现代医药卫生，2018，11（34）：3339-3341，3416.
|
| [11] |
赵祺，刘珈，罗凌嵘，等.腹腔热灌注化疗联合rhIL-2 序贯疗法治疗恶性腹腔积液的近期疗效观察[J].肿瘤药学，2018，8（5）：775-778，790.
|
| [12] |
刘静，黄琰.恩度联合顺铂腹腔热灌注治疗恶性腹水的疗效及对VEGF 的影响[J].潍坊医学院学报，2019，41（1）：13-15.
|
| [13] |
张红，熊宗红.分析阿帕替尼联合顺铂腹腔灌注治疗卵巢癌恶性腹腔积液的有效性[J].中外医学研究，2019，17（21）：139-141.
|
| [14] |
Chen WC，Qiu JT，Lai CH，et al.Outcomes and prognoses of patients with ovarian cancer using bevacizumab：6-year experience in a tertiary care hospital of northern Taiwan[J].PLoS One，2017，12（5）：e0175703.
|
| [15] |
胡永华，范宇飞，李定纲.顺铂序贯榄香烯联合热疗治疗恶性胸腔积液的效果分析[J].中国当代医药，2016，11（23）：74-76.
|
| [16] |
秦苑，任东，范宇飞.腹腔内灌注重组人p53 腺病毒注射液及顺铂结合局部亚高温热疗治疗恶性腹水观察[J].实用临床医药杂志，2011，15（13）：15-17.
|
|
|
|
